SLU-PP-332

  • SLU-PP-332 is a synthetic compound that functions as a potent agonist for estrogen-related receptors (ERRα, ERRβ, and ERRγ), with the highest affinity for ERRα. By activating these receptors, SLU-PP-332 enhances mitochondrial function and cellular respiration in muscle cells, effectively mimicking the physiological effects of exercise. This activation leads to increased energy expenditure, improved fatty acid oxidation, and a reduction in fat mass accumulation.

    • Enhanced Energy Expenditure: Increases the body’s basal metabolic rate, leading to higher calorie burn.

    • Improved Fatty Acid Oxidation: Enhances the body’s ability to utilize fat as an energy source, promoting fat loss.

    • Reduction in Fat Mass: Decreases fat accumulation, contributing to weight loss.

    • Enhanced Mitochondrial Function: Improves the efficiency of cellular energy production.

    • Increased Exercise Endurance: Boosts stamina and endurance by promoting the development of fatigue-resistant muscle fibers.

    • Improved Insulin Sensitivity: Enhances the body’s response to insulin, aiding in better blood sugar control.

    • Potential Cardioprotective Effects: May improve heart function by enhancing cardiac fatty acid metabolism and reducing fibrosis.

    • Muscle Preservation: Helps maintain muscle mass during periods of inactivity or caloric restriction.

    • Anti-Inflammatory Properties: Exhibits potential in reducing inflammation in various tissues.

    • Neuroprotective Potential: May offer protective effects against neurodegenerative conditions.

    • Obesity Treatment: Aids in weight loss by increasing energy expenditure and reducing fat mass.

    • Metabolic Syndrome Management: Addresses components of metabolic syndrome, such as insulin resistance and dyslipidemia.

    • Type 2 Diabetes Support: Improves insulin sensitivity and glucose metabolism.

    • Heart Failure Therapy: Enhances cardiac function by improving energy metabolism in heart cells.

    • Muscle Atrophy Prevention: Prevents muscle loss in conditions leading to muscle wasting.

    • Exercise Mimetic: Provides benefits similar to exercise for individuals unable to engage in physical activity.

    • Non-Alcoholic Fatty Liver Disease (NAFLD) Treatment: Reduces liver fat accumulation and improves liver function.

    • Kidney Disease Management: Offers potential protective effects in renal conditions.

    • Cognitive Function Support: May enhance cognitive abilities and protect against neurodegenerative diseases.

    • Anti-Inflammatory Applications: Utilized in conditions where reducing inflammation is beneficial.

  • References:

    1. Nasri, H. (2024). New hopes on “SLU-PP-332” as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view. Journal of Renal Endocrinology, 10, e25143. 

    2. Elgendy, S., et al. (2024). Mimicking exercise with a pill. American Chemical Society. 

    3. Billon, C., et al. (2023). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics, 376(3), 397-409.

    4. Burris, T. P., et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology, 18(4), 1000-1009.

    5. Elgendy, S., et al. (2024). Exercise in a Pill? Breakthrough Mimics Workout Benefits. Neuroscience News. 

    6. University of Florida Health. (2023). Exercise-mimicking drug sheds weight, boosts muscle activity in mice. UF Health News. 

    7. Medical News Today. (2023). New drug may help lose weight, reduce fat by mimicking exercise. Medical News Today. 

    8. American Chemical Society. (2024). Mimicking exercise with a pill. ACS Press Release. 

    9. ScienceAlert. (2023). New Drug Mimics Exercise, Causing Obese Mice to Burn Fat And Lose Weight. ScienceAlert. 

    10. ZME Science. (2024). Exercise in a pill: New compounds may mimic the effects of physical activity. ZME Science.